Category Archives: Patently BIOtech

IP Sessions at BIO 2016–Come Join us in San Francisco!

BIO CONVENTION LOGO_VERTICAL_D_CMYK

That’s right, we’re back at it again! This year’s BIO International Convention will host several innovative educational sessions on the state of intellectual property in the biotech sector.   BIO‘s top-notch education program covers the biotechnology and pharma industry’s most relevant and timely topics in intellectual property.  In each session, top thought leaders will offer insights on issues essential to the industry and provide a wealth of information of strategic relevance to the IP biotech sector.  Well, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Join us for the IP Symposium at the 2016 BIO World Congress!

World Congress-BIOFacebook_12000x1200

Ah, San Diego. What is it they say about you? Come for the beaches…. Stay for the fish tacos. Here at BIO, we’ll admit it—San Diego, you have enticed us with your perpetual 65° temperatures. And it’s the perfect time to join BIO and the 1,200 attendees from 50 countries at the 2016 BIO World Congress, the world’s largest industrial biotechnology event! But wait…THERE’S MORE? We couldn’t be more excited to announce that BIO will Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

What We’ll Be Talking about at the BIO Spring IPCC Conference

IPCC Logo

It’s time once again for BIO’s Spring IPCC Conference! BIO’s biannual Intellectual Property Counsels Committee Conference provides informative and interesting educational sessions on what’s happening in the biotech IP sector. It also provides a chance to network with industry colleagues, promoting discussion and fostering new and exciting relationships. Attendees represent all swaths of the biotech sector, including pharma companies, law firms, academia and government, coming together from the U.S. and abroad to attend this one Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

“II Ca-Be-lly, or Not II Ca-Be-lly?”: Is The Famous Cabilly II Antibody Patent Near Extinction?

N_logo_2clr

Guest post by Konstantin Linnik, Ph.D., Isaac Hubner, Ph.D, and Lana Gladstein, who are attorneys in the Boston office of Nutter McClennen & Fish LLP. On February 5, 2016, the Patent Trial and Appeal Board (“PTAB”) issued a decision to institute an Inter Partes Review (“IPR”) of Genentech’s “Cabilly II” patent (U.S. Patent No. 6,331,415). This triggered the one-month deadline for third parties to request joinder under 37 CFR § 42.122(b).  Whether you are a licensee, or otherwise Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Patently Biotech’s Top Articles of 2015

Intellectual property and patent reform have dominated headlines in 2015. As we close out the year, let’s take a look at some of this year’s most memorable Patently BIOtech coverage. Here are Patently Biotech’s top blog posts of 2015: This Independence Day, Let’s Thank the Inventors IP Sessions at BIO 2015: The Impact of the Inter Partes Review on (BIO)Pharma FDA Acts on Biosimilars Seventy Nine House Members Express Concern with H.R. 9 Make sure Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post